Medical Condition News

RSS

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Beginner's guide to cancer

An academic from The University of Nottingham has written the first introductory guide to cancer, covering everything from the biology of the disease and why some people are more at risk of developing it than others, to the latest research into prevention, treatment and cure.

4 Nov 2010

Exposure to several AEDs in the womb negatively affect child's neurodevelopment

A large population-based study revealed that multiple antiepileptic drugs (AEDs) used by pregnant women to control seizures may cause poor school performance in their teenagers. The research team from Karolinska University Hospital and the University of Lund in Sweden confirmed that exposure to AEDs in utero may have a negative effect on neurodevelopment.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

Low vitamin D levels linked to cancer progression and death in CLL patients

Researchers at Mayo Clinic have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D levels in their blood compared to those who didn't.

4 Nov 2010

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

Researchers at the University of Cincinnati (UC) and the Cincinnati Veterans Affairs (VA) Medical Center have found that about one-third of chronic kidney disease patients who are prescribed therapies for high blood pressure do not often adhere to treatments.

4 Nov 2010

Study identifies promising therapy to overcome limitation in brain's ability to recover function after stroke

Stroke is the leading cause of adult disability, due to the brain's limited capacity for recovery. Physical rehabilitation is the only current treatment following a stroke, and there are no medications available to help promote neurological recovery.

4 Nov 2010

Rescu receives $50,000 grant to teach 22 minute CPR course to high school students

Researchers led by St. Michael's Hospital will be teaching a quick, inexpensive method of cardio-pulmonary resuscitation to some Toronto-area high school students this fall.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3.

4 Nov 2010

Coronado completes series of private financings

Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.

4 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.

4 Nov 2010

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

The Endocrine Society released a new clinical practice guideline for the nutritional and endocrine management of adults after bariatric surgery, including those with diabetes mellitus. The guideline features a series of evidence-based clinical recommendations developed by an expert task force. The guideline is published in the November 2010 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Medical Condition News

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Phase III study suggests CYCLOSET tablets improve glycemic control

Beginner's guide to cancer

Exposure to several AEDs in the womb negatively affect child's neurodevelopment

Gene fusion prostate cancers susceptible to secondary mutations

Aestus receives $244,000 grant from QTDP program

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

New findings show combinational therapy effective for patients with DLBCL lymphoma

Low vitamin D levels linked to cancer progression and death in CLL patients

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

Study identifies promising therapy to overcome limitation in brain's ability to recover function after stroke

Rescu receives $50,000 grant to teach 22 minute CPR course to high school students

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Coronado completes series of private financings

New noninvasive technique provides low-level electrical stimulation to reduce pain

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News